⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971066 | 0.84 | — | — | |
| SCHEMBL11918034 | 0.55 | ALDH1A1 (0.30) | — | |
| SCHEMBL21306240 | 0.55 | KDM4E (0.32) | — | |
| SCHEMBL175478 | 0.55 | ALDH1A1 (0.33) | — | |
| SCHEMBL10600250 | 0.53 | NOTUM (0.30) | — | |
| SCHEMBL24604 | 0.45 | — | — | |
| SCHEMBL14721708 | 0.45 | — | — | |
| SCHEMBL444758 | 0.45 | — | — | |
| SCHEMBL6544822 | 0.43 | — | — | |
| SCHEMBL1052909 | 0.43 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347568-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | THE SCRIPPS RESEARCH INSTITUTE | 2024-03-21 | — | — | US | claimed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | claimed |
| US-20220002311-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-01-06 | — | — | US | claimed |
| EP-3898592-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| WO-2020132653-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | claimed |
| WO-2013078413-A1 | MODULATORS OF LIPID STORAGE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-30 | — | — | WO | claimed |
| EP-4347568-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | THE SCRIPPS RESEARCH INSTITUTE | 2024-03-21 | — | — | US | disclosed |
| WO-2024037617-A1 | POLYMER FILMS, METHODS FOR PREPARING THEREOF, AND COMPOSITE CURRENT COLLECTORS THEREOF | JIANGYIN NANOPORE INNOVATIVE MATERIALS TECHNOLOGY LTD (CN) | 2024-02-22 | — | — | WO | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20220017471-A1 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | UNIV SHANGHAI TECHNOLOGY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220002311-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-01-06 | — | — | US | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| US-6894161-B2 | Methods and compositions for photo-cross linking photoactive compounds to target tissue | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2005-05-17 | — | — | US | disclosed |
| US-20030013696-A1 | Methods and compositions for photo-cross linking photoactive compounds to target tissue | BRITISH COLUMBIA, UNIVERSITY OF, THE (CA) | 2003-01-16 | — | — | US | disclosed |
| WO-2002076453-A1 | METHODS AND COMPOSITIONS FOR PHOTO-CROSS LINKING PHOTOACTIVE COMPOUNDS TO TARGET TISSUE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-10-03 | — | — | WO | disclosed |